GlassScriptPhysician profile
Susan Candelaria
NPI 1992396998
$5,016.45
in general payments reported to CMS, 2019-2025
21 companies · $1,619 in 2025
The $1,619 reported for 2025 was more than what 89% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $376 · 2022: $870 · 2023: $952 · 2024: $1,199 · 2025: $1,619.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,770.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,769.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,037.88 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $816.49 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $719.60 | 2022-2025 | Spravato |
| Otsuka America Pharmaceutical, INC. | $653.34 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $288.32 | 2021-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $197.27 | 2023-2025 | Ingrezza |
| Almatica Pharma LLC | $194.63 | 2022-2023 | Loreev Xr |
| Indivior INC. | $159.49 | 2021-2025 | Sublocade |
| Lundbeck LLC | $158.09 | 2022-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $141.72 | 2024-2025 | Cobenfy |
| Braeburn INC. | $138.55 | 2024-2025 | Brixadi |
| Vanda Pharmaceuticals INC. | $129.53 | 2022-2024 | Fanapt, Hetlioz |
| Sunovion Pharmaceuticals INC. | $86.35 | 2022 | |
| Axsome Therapeutics, INC. | $76.49 | 2022-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $52.96 | 2024-2025 | Trintellix |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $49.10 | 2024-2025 | Zurzuvae |
| Supernus Pharmaceuticals, INC. | $44.24 | 2024-2025 | Qelbree |
| Soleno Therapeutics, INC. | $25.88 | 2025 | Vykat Xr |
| Neuronetics, INC. | $18.11 | 2021 | |
| Bausch Health US, LLC | $15.77 | 2022 | |
| Corium, LLC | $12.64 | 2024 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Candelaria listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.